| Typicality: | 0.365 |
| Saliency: | 0.269 |
| in august | 4 | temporal |
| at each investigative site | 3 | location |
| in approximately 20 years | 2 | temporal |
| trial → be approved by → the fda | 12 |
| trial → be cleared by → the fda | 4 |
| negative | neutral | positive |
| 0.137 | 0.630 | 0.233 |
| Raw frequency | 16 |
| Normalized frequency | 0.269 |
| Modifier score | 0.500 |
| Perplexity | 289.463 |